Biotech: Page
-
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
Safety risks highlighted in FDA letter on Sarepta's Vyondys
In rejecting Vyondys last August, one FDA official wrote that, without confirmatory trials for either of Sarepta's muscular dystrophy drugs, it's difficult to judge whether they're worth the risk.
By Jonathan Gardner • Jan. 22, 2020 -
Drug trial success a consolation prize for Akcea, Ionis
Although Novartis chose not to license Akcea and Ionis' high triglyceride drug, positive data could open up new development opportunities.
By Ned Pagliarulo • Jan. 22, 2020 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
5 biopharmas to watch as the decade's last earnings kick off
Biogen faces down analysts one more time on its aducanumab plans, while two biotechs could give early glimpses into their first-ever drug launches.
By Ned Pagliarulo , Jacob Bell • Jan. 21, 2020 -
After big year, RNAi drugmakers compete to prove what comes next
"We are in the first out of the first inning of the lifespan of RNAi," said Arrowhead CEO Christopher Anzalone. Two RNAi drugs are now approved, but the field still has much to prove.
By Andrew Dunn • Jan. 17, 2020 -
BioNTech rescues cancer biotech Neon in bargain buyout
The all-stock deal, worth $67 million, valued Neon at a 86% discount to the cell therapy developer's IPO price of $16 per share.
By Ned Pagliarulo • Jan. 16, 2020 -
Orchard isn't for the picking, Biohaven's Allergan headache, and who's on Vascepa?
Amarin CEO John Thero had one question for investors eager to hear about his company's plans for its heart pill, while Orchard made a case for independence.
By Jacob Bell • Jan. 16, 2020 -
Nektar quickly drops opioid drug after FDA panel rejection
After a decade of research, the biotech said it will withdraw its application for oxycodegol and make no further investment in the drug.
By Kristin Jensen • Jan. 15, 2020 -
Galapagos finds a new normal at biotech's biggest dealmaking event
Though the Belgian drug company is tied to a 10-year, $5 billion research pact with Gilead, its CEO says there's still some "wheeling and dealing" left to do.
By Jacob Bell • Jan. 15, 2020 -
Neuroscience's decade, a biotech's 'crown jewel,' and Ionis gets selective
Roche, maker of the last decade's top cancer drugs, is betting that neuroscience R&D can make strides in the 2020s — an outlook that contrasts with research retreats by the pharma's peers.
By Andrew Dunn , Jacob Bell • Jan. 15, 2020 -
Astellas swoops in for Adaptimmune deal a day after positive data
For $50 million, the Japanese pharma signed up for three programs in a deal that could net Adaptimmune hundreds of millions more if all goes to plan.
By Jonathan Gardner • Jan. 14, 2020 -
Alexion's neuro bet, Rubius' trial troubles and biotech's gene therapy milestones
On the first day of the JPM conference, Alexion mapped out ambitious plans in neuroscience, while Rubius did its best to explain delays in testing its first drug.
By Jacob Bell , Andrew Dunn • Jan. 14, 2020 -
BioMarin sets gene therapy sights beyond hemophilia
At the JPM conference, the biotech announced a manufacturing lift and a new trial start that affirm its ambitions in gene therapy go beyond its closely watched hemophilia A treatment.
By Jacob Bell • Jan. 13, 2020 -
Biogen finds $75M home for Pfizer Alzheimer's drug
Having stepped back from neuroscience research, Pfizer will sell off an early-stage therapy to Biogen, which has made the space its central focus.
By Jonathan Gardner • Jan. 13, 2020 -
Incyte turns to German Morphosys to refresh cancer pipeline
A licensing deal for Morphosys' near-to-market lymphoma drug will pad a pipeline that was recently weakened by a surprising study setback for Incyte.
By Ned Pagliarulo • Jan. 13, 2020 -
Blueprint wins 1st FDA approval with targeted cancer drug
The Boston-area biotech advanced Ayvakit from initial human testing to regulatory approval in just four years, a rapid timeline reflective of the drug's gene-targeted profile.
By Ned Pagliarulo • Jan. 10, 2020 -
5 biotech trends to follow in 2020
Enthusiasm for new drugs and burgeoning companies will collide with an election year spotlight.
By Ned Pagliarulo • Jan. 9, 2020 -
Moderna, though early in development, prepares its vaccine for market
The vaccine just began mid-stage testing, but Moderna is already preparing for the next steps, which include a large Phase 3 study and hiring of sales associates.
By Jacob Bell • Jan. 9, 2020 -
Solid cuts one-third of staff, goes all in on delayed gene therapy
Re-starting a halted muscular dystrophy trial is Solid's priority as it puts a second drug and an assistive device on the backburner.
By Jonathan Gardner • Jan. 9, 2020 -
Lilly looms over Blueprint as the biotech files targeted cancer drug
Positive results in certain lung cancer patients support Blueprint's decision to submit pralsetinib, a RET-inhibitng drug, for approval in the first quarter.
By Jacob Bell • Jan. 8, 2020 -
Alexion's blockbuster Soliris bested by Apellis in Phase 3 trial
The study result sent shares in Apellis up by more than 20%, as investors saw potential for the Massachusetts biotech to take on Alexion's top-seller.
By Andrew Dunn • Jan. 7, 2020 -
Retrieved from National Cancer Institute on September 27, 2019
Merck adds to lung cancer wall with Otsuka deal
The $50 million deal with two Japanese biotechs is a small bet to match challengers in Amgen and Mirati, who are advancing agents targeting KRAS mutations.
By Jonathan Gardner • Jan. 6, 2020 -
Trial failure keeps Incyte searching for its next act
A setback for Incyte's experimental drug itacitinib adds to a list of pipeline disappointments for the Delaware biotech.
By Ned Pagliarulo • Jan. 3, 2020 -
Wave's Huntington's drug shows effect but falls short of mark set by Roche and Ionis
The gene-targeting drug lowered levels of a damaging mutant protein, but the therapy's modest effect disappointed investors.
By Jonathan Gardner • Jan. 2, 2020 -
Intra-Cellular approval keeps focus on FDA's neuroscience review process
Lumateperone, to be sold as Caplyta, had conflicting results in late-stage trials. Its approval suggests the FDA is using a "glass half full lens" to review neuroscience drugs, said one analyst.
By Jacob Bell • Dec. 23, 2019 -
Roche hands $1B to Sarepta in major return to gene therapy deals
The Swiss pharma acquired a muscular dystrophy treatment for markets outside the U.S. in a pact that could reach a value of $10 billion.
By Jonathan Gardner • Dec. 23, 2019